Pitt's Microneedle Patches Target Rural PA Vaccine Gaps

Scientists at the University of Pittsburgh have developed dissolvable microneedle array patches, fingertip-sized innovations with hundreds of tiny, sugar-based needles that deliver vaccines directly into the skin for a stronger immune response. Tested successfully in mice for COVID-19, the patches produced neutralizing antibodies by dissolving within minutes, bypassing painful hypodermic shots.[5] Originally reported by WHP CBS 21 Harrisburg, the technology addresses low vaccination rates in rural Pennsylvania, where counties like Tioga and Elk face barriers including long drives to clinics and needle phobia.[1][5] Pitt's platform, refined over years, powers applications beyond vaccines, including skin cancer treatments licensed to Pittsburgh startup SkinJect, Inc. Developed by Dermatology Chair Louis Falo, M.D., and Carnegie Mellon Professor O. Burak Ozdoganlar, Ph.D., the SkinJect patch deploys weekly for three weeks in doctors' offices, dissolving in 15 minutes to kill basal cell and squamous cell carcinomas without surgery's pain or cost.[1][3] Panther Life Sciences is commercializing similar microneedle arrays as hypodermic alternatives, with Pitt's BioForge supporting market entry.[2][6] In Pennsylvania's rural heartland, where 2025 state data showed vaccination coverage dipping below 60% in some Appalachian counties, these patches promise clinic-free delivery via mail or local stores. Pitt researchers highlight the skin's immune potency, making microneedles ideal for vaccines and therapies like hair loss treatments in trials elsewhere.[4][7] As the university pushes FDA pathways—SkinJect eyed IND filings years ago—state health officials eye pilots for flu and COVID boosters in underserved regions.[3][5] The technology's shelf stability and patient-friendly design earned high acceptance in early feedback, positioning Pittsburgh as a hub for equitable health innovations tailored to Pennsylvania's 3 million rural residents.[3][7]